Germany approves first trial of COVID-19 vaccine candidate

As per reports, Germany’s vaccines regulator has approved live human testing of a potential vaccine against the COVID 19 virus developed by German biotech company BioNTech.

Deccan Herald mentioned in an article that the regulator said it in a statement on Wednesday.

As per reports, the trial, only the fourth worldwide of a preventive agent targeting the virus behind the global pandemic, will be conducted on 200 healthy people ages between 18 and 55 in the first stage, and on further people, including those at higher risk from the disease, in a second stage.

As per media reports, BioNTech said it was developing the vaccine candidate, named VNT162, together with its partner, pharma giant Pfizer. Tests of the vaccine were also planned in the United States, once regulatory approval for testing on humans had been secured there.

(With inputs from Deccan Herald)

Leave A Reply

Your email address will not be published.